In vitro and in vivo enhancement of osteogenic capacity in a synthetic BMP‐2 derived peptide‐coated mineralized collagen composite. (31st January 2013)

• Record Type: Journal Article
• Authors: Zhang, Xue; Guo, Wen‐Guang; Cui, Helen; Liu, Huan‐Ye; Zhang, Yang; Müller, Werner EG; Cui, Fu‐Zhai
• Is Part Of: Journal of tissue engineering and regenerative medicine. Volume 10:Number 2(2016)
• Page Start: 99
• Page End: 107
• Publication Date: 2013-01-31
• Subjects: nano‐hydroxyapatite/collagen -- marrow stromal cells -- P17‐BMP‐2 -- osteoblastic differentiation -- bone regeneration -- bone tissue engineering; Tissue engineering -- Periodicals; Regeneration (Biology) -- Periodicals; 610.28
• DOI: 10.1002/term.1705
• Languages: English
• ISSNs: 1932-6254

Abstract

Abstract: Enhancement of osteogenic capacity was achieved in a mineralized collagen composite, nano‐hydroxyapatite/collagen (nHAC), by loading with synthetic peptides derived from BMP‐2 residues 32‐48 (P17‐BMP‐2). Rabbit marrow stromal cells (MSCs) were used in vitro to study cell biocompatibility, attachment and differentiation on the mineralized collagen composite by a cell counting kit, scanning electron microscopy (SEM) and real‐time reversed transcriptase‐polymerase chain reaction analysis (RT‐PCR). Optimal peptide dosage (1.0 µg/mL) was obtained by RT‐PCR analysis in vitro . In addition, the relative expression level of OPN and OCN was significantly upregulated on P17‐BMP‐2/nHAC compared with nHAC. In vitro results of P17‐BMP‐2 release kinetics demonstrated that nHAC released P17‐BMP‐2 in a controlled and sustained manner. In the rabbit mandibular box‐shaped bone defect model, osteogenic capacity of three groups (nHAC, P17‐BMP‐2/nHAC, rhBMP‐2/nHAC) was evaluated. Compared to the nHAC group, bone repair responses in both P17‐BMP‐2/nHAC and rhBMP‐2/nHAC group implants were significantly improved based on histological analysis. The osteogenic response of the P17‐BMP‐2/nHAC group was similar to that of the rhBMP‐2/nHAC group. Copyright © 2013 John Wiley & Sons, Ltd.